[go: up one dir, main page]

AU2002215345A1 - Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer - Google Patents

Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Info

Publication number
AU2002215345A1
AU2002215345A1 AU2002215345A AU1534502A AU2002215345A1 AU 2002215345 A1 AU2002215345 A1 AU 2002215345A1 AU 2002215345 A AU2002215345 A AU 2002215345A AU 1534502 A AU1534502 A AU 1534502A AU 2002215345 A1 AU2002215345 A1 AU 2002215345A1
Authority
AU
Australia
Prior art keywords
methods
prostate cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215345A
Inventor
Daniel Afar
Kurt C. Gish
Peter Hevezi
David H. Mack
Keith E. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/847,046 external-priority patent/US20020068036A1/en
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Publication of AU2002215345A1 publication Critical patent/AU2002215345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57555—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2002215345A 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer Abandoned AU2002215345A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US68757600A 2000-10-13 2000-10-13
US09/687,576 2000-10-13
US73328800A 2000-12-08 2000-12-08
US73374200A 2000-12-08 2000-12-08
US09/733,742 2000-12-08
US09/733,288 2000-12-08
US26395701P 2001-01-24 2001-01-24
US60/263,957 2001-01-24
US27679101P 2001-03-16 2001-03-16
US27688801P 2001-03-16 2001-03-16
US60/276,791 2001-03-16
US60/276,888 2001-03-16
US28192201P 2001-04-06 2001-04-06
US60/281,922 2001-04-06
US28621401P 2001-04-24 2001-04-24
US60/286,214 2001-04-24
US09/847,046 US20020068036A1 (en) 2000-10-13 2001-04-30 Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US09/847,046 2001-04-30
US28858901P 2001-05-04 2001-05-04
US60/288,589 2001-05-04
PCT/US2001/032045 WO2002030268A2 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Publications (1)

Publication Number Publication Date
AU2002215345A1 true AU2002215345A1 (en) 2002-04-22

Family

ID=27581207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215345A Abandoned AU2002215345A1 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Country Status (6)

Country Link
EP (1) EP1474528A4 (en)
JP (1) JP2005506033A (en)
AU (1) AU2002215345A1 (en)
CA (1) CA2425569A1 (en)
MX (1) MXPA03003151A (en)
WO (1) WO2002030268A2 (en)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402947T3 (en) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, PCA3 genes and methods of use
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2329851T3 (en) 1998-06-01 2009-12-01 Agensys, Inc. NEW TRANSMEMBRANABLE ANTIGENS EXPRESSED IN HUMAN CANCER AND USING THEMSELVES.
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE60027027T2 (en) 1999-09-29 2006-11-30 Diagnocure Inc. PCA3 MRNA IN GOOD AND MASTILE PROSTATE WEAVE
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US20020187524A1 (en) * 2000-12-15 2002-12-12 Millennium Pharmaceuticals, Inc. 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, and 67084 alt, human proteins and methods of use thereof
DE60134178D1 (en) * 2000-07-28 2008-07-03 Ulrich Wissenbach TRP8 CANCER MARKER
US20030092009A1 (en) 2000-11-16 2003-05-15 Kaia Palm Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
EP1385884A2 (en) * 2001-03-05 2004-02-04 Aventis Pharma S.A. Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR100603488B1 (en) * 2001-06-20 2006-07-24 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
EP1499350A4 (en) * 2001-08-31 2006-02-08 Agensys Inc NUCLEIC ACID AND CORRESPONDING PROTEIN CURED 205P1B5 FOR THE TREATMENT AND DETECTION OF CANCER
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005505271A (en) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
JP2005519137A (en) * 2001-09-17 2005-06-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Methods for using 46828 human acyl-CoA synthetase
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2005067629A2 (en) * 2004-01-06 2005-07-28 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
DE60328979D1 (en) * 2002-05-10 2009-10-08 Jackson H M Found Military Med ANDROGEN-REGULATED PMEPA1 GENE AND METHOD FOR ITS USE TO INHIBIT CANCER GROWTH
DE10234901A1 (en) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh New nucleic acids encoding Mrp4, useful in the diagnosis of prostatic, bladder and ovarian tumors, also in screening for specific binding agents, and potential therapeutic agents
WO2004015108A1 (en) * 2002-08-09 2004-02-19 Melbourne Health Mammalian grainyhead transcription factors
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2003282785A1 (en) * 2002-08-26 2004-03-11 Case Western Reserve University Methods for treating patients and identifying therapeutics
AU2003283427A1 (en) * 2002-12-09 2004-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
JP2004357702A (en) * 2003-05-09 2004-12-24 Research Association For Biotechnology New protein and dna encoding the same
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
NZ547633A (en) 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP2007525203A (en) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 EphA4 as a therapeutic target for PRC and PDACa
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2005106488A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US20090004193A1 (en) * 2004-07-23 2009-01-01 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Vasoactive Intestinal Peptide Receptor 1 (Vpac1)
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
JP4993645B2 (en) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド Antibody drug conjugates and methods
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2006074914A2 (en) * 2005-01-13 2006-07-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Human rna helicase and therapeutic uses thereof
DK2325305T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
DK2061814T3 (en) 2006-10-27 2012-08-27 Genentech Inc Antibodies and immunoconjugates and their use.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2736170A1 (en) * 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
EP3106875B1 (en) * 2007-10-25 2020-04-29 Toray Industries, Inc. Method for detection of cancer
JP5589274B2 (en) * 2007-10-25 2014-09-17 東レ株式会社 Immune inducer
AU2014240339B2 (en) * 2007-10-25 2017-07-13 Toray Industries, Inc. Method for detection of cancer
EP2303332B1 (en) 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (en) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Hig2 and urlc10 epitope peptide and vaccines containing the same
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
EP2528625B1 (en) 2010-04-15 2013-07-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
PE20130460A1 (en) * 2010-05-03 2013-04-26 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
JP2013534520A (en) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 A Multiple Reaction Monitoring LC-MS/MS Method for the Detection of Therapeutic Antibodies in Animal Samples Using Framework Signature Peptides
RS54446B1 (en) 2011-10-14 2016-06-30 Medimmune Limited PIROLOBENZIDIAZEPINE AND ITS CONJUGATES
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
PT2906251T (en) 2012-10-12 2017-12-04 Medimmune Ltd CONJUGATES OF PYRROLOBENZODIAZEPINA-ANTIBODY ANTI-CD22
JP6270859B2 (en) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ Pyrrolobenzodiazepine-antibody conjugate
ES2530968T3 (en) 2012-10-12 2015-03-09 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
TR201808051T4 (en) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates.
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
EA032986B1 (en) 2012-12-21 2019-08-30 Медимьюн Лимитед Pyrrolobenzodiazepines
CA2894961C (en) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20150132500A (en) * 2013-03-15 2015-11-25 메타마크 제네틱스, 인크. Compositions and methods for cancer prognosis
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
MX2016007578A (en) 2013-12-16 2016-10-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
JP6671292B2 (en) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc drug and antibody conjugates, compounds, treatment method and pharmaceutical composition
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
JP6622293B2 (en) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
PE20170905A1 (en) 2014-09-17 2017-07-12 Genentech Inc PYROLOBENZODIAZEPINES AND ANTIBODY-DISULFIDE CONJUGATES THEREOF
JP6878287B2 (en) 2014-11-25 2021-05-26 アーデーセー セラピューティクス ソシエテ アノニム Pyrrolobenzodiazepine-antibody conjugate
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2871001T3 (en) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugates of pyrrolobenzodiazepines and antibodies
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
KR102189731B1 (en) 2017-04-18 2020-12-11 메드임뮨 리미티드 Pyrrolobenzodiazepine conjugate
MX2019012464A (en) 2017-04-20 2019-12-11 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate.
BR112019026564A2 (en) 2017-06-14 2020-06-30 Adc Therapeutics Sa dosing regimens for administration of an anti-cd19 adc
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20210318324A1 (en) * 2018-07-05 2021-10-14 The Board Of Regents Of The University Of Oklahoma Gene signatures for cancer characterization and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (en) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR102890251B1 (en) 2019-03-15 2025-11-25 메드임뮨 리미티드 Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
TW202432187A (en) 2022-12-23 2024-08-16 美商建南德克公司 Cereblon degrader conjugates, and uses thereof
CN121263210A (en) 2023-04-17 2026-01-02 沛科生物公司 Antibodies and antibody-drug conjugates, as well as their usage, synthesis processes, and intermediates
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
CN119215114A (en) * 2024-12-03 2024-12-31 浙江理工大学 Application of lily extracellular vesicles in preparing tumor therapeutic drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976794A (en) * 1994-04-15 1999-11-02 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
EP1047793B1 (en) * 1998-01-21 2006-11-15 Dianon Systems, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AU756384B2 (en) * 1998-02-23 2003-01-09 Dana-Farber Cancer Institute, Inc. Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
AU2001241415A1 (en) * 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Also Published As

Publication number Publication date
JP2005506033A (en) 2005-03-03
WO2002030268A2 (en) 2002-04-18
EP1474528A2 (en) 2004-11-10
WO2002030268A3 (en) 2004-08-26
MXPA03003151A (en) 2003-08-19
CA2425569A1 (en) 2002-04-18
EP1474528A4 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002068677A8 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002257004A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2001249317A1 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer